Literature DB >> 20362225

Analysis of fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection of early bladder cancer.

Jong-Ha Yoo1, Borum Suh, Tae Sung Park, Myung-Geun Shin, Yeung Deuk Choi, Chang Hoon Lee, Jong Rak Choi.   

Abstract

We designed this study to test the sensitivities of cytology, the nuclear matrix protein 22 (NMP22) assay, and fluorescence in situ hybridization (FISH) in the early detection of urothelial carcinoma, and to identify mtDNA alterations in urinary epithelial cells. We collected 41 urine samples and 26 corresponding peripheral blood samples from patients with clinically suspected urothelial carcinoma. The FISH and NMP22 assays detected 92.1% of the cancers, and cytology detected 60.5%. In the low-grade group, NMP22 and FISH analyses were more sensitive than cytology, but in the high-grade group, all three methods showed approximately 90% sensitivity. Overall, the FISH and NMP22, or FISH and cytology assays combined detected 97.4% of cancers, while cytology with NMP22 detected 92.1%. In the low-grade group, the sensitivity of the three methods combined was above 80%, but in high-grade group, the combined sensitivity was approximately 100%. In the mtDNA control region, we detected characteristic heteroplasmic mtDNA substitution mutations in 1 patient and a mtDNA length heteroplasmic mutation in 303 polyC or 16184 poly C in 20 patients. Overall, urothelial carcinoma-specific mtDNA mutations were observed in 20 of the 26 patients (76.9%). The average mtDNA copy numbers in urine samples and corresponding peripheral blood samples (83.45 +/- 60.36 and 39.0 +/- 24.38, respectively) (mean +/- standard deviation [SD]) differed significantly (P < 0.001). The mtDNA copy numbers in the urine samples from patients with high-grade and low-grade tumors (81.83 +/- 67.78 and 86.49 +/- 46.69, respectively) did not differ significantly (P = 0.589). In conclusion, the FISH assay showed the highest sensitivity for detecting low-grade urothelial carcinoma, and mtDNA copy numbers in urine samples were higher than those in the corresponding peripheral blood samples. The frequency of mtDNA mutations in the D-loop region in patients with cancer was approximately 80% in our study. This report further supports the significance of genetic alteration in urothelial carcinoma and the clinical utility of the FISH, mtDNA quantitation polymerase chain reaction, mtDNA sequencing, and capillary electrophoresis for this purpose. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362225     DOI: 10.1016/j.cancergencyto.2009.12.017

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

Review 1.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

2.  Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms.

Authors:  Stephen B Williams; Yuanqing Ye; Maosheng Huang; David W Chang; Ashish M Kamat; Xia Pu; Colin P Dinney; Xifeng Wu
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-20

3.  Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients.

Authors:  Santanu Dasgupta; Chunbo Shao; Thomas E Keane; David P Duberow; Richard A Mathies; Paul B Fisher; Lambertus A Kiemeney; David Sidransky
Journal:  Int J Cancer       Date:  2011-08-30       Impact factor: 7.396

4.  Targeting bladder tumor cells in voided urine of Chinese patients with FITC-CSNRDARRC peptide ligand.

Authors:  Xing-You Jia; Qi Yu; Zhe-Hui Zhang; Xiao-Feng Yang
Journal:  Onco Targets Ther       Date:  2012-05-07       Impact factor: 4.147

Review 5.  Mitochondrial DNA aberrations and pathophysiological implications in hematopoietic diseases, chronic inflammatory diseases, and cancers.

Authors:  Hye-Ran Kim; Stephanie Jane Won; Claire Fabian; Min-Gu Kang; Michael Szardenings; Myung-Geun Shin
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

Review 6.  MtDNA As a Cancer Marker: A Finally Closed Chapter?

Authors:  Elmar Kirches
Journal:  Curr Genomics       Date:  2017-06       Impact factor: 2.236

7.  Comparison of the diagnostic performance of fluorescence in situ hybridization (FISH), nuclear matrix protein 22 (NMP22), and their combination model in bladder carcinoma detection: a systematic review and meta-analysis.

Authors:  Qindong Liang; Guangjie Zhang; Wuxian Li; Jing Wang; Shangchun Sheng
Journal:  Onco Targets Ther       Date:  2018-12-31       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.